Professor Nir Barzilai, director and founder of the Institute for Aging Research at Yeshiva University’s Albert Einstein College of Medicine, has more reason than most to believe that this is not far from the truth.
These days, Barzilai is working on an ambitious new project that is making waves globally. If it succeeds, it could start a total revolution in how we treat illness and aging.
Barzilai is overseeing a clinical trial titled “Targeting Aging with Metformin”, or TAME, which seeks to discover whether Metformin, a medication prescribed for diabetes, may also delay the onset of aging-related illnesses, such as cancer, heart disease, and cognitive impairment.
The trial is currently in the final stages of planning and is searching for further sources of funding. The planned trial is to involve administering Metformin to thousands of elderly people, some of whom suffer from the aforementioned illnesses, and some of whom have the potential to develop the illnesses. Another group of subjects, identical in makeup to the first, is to be given a placebo as a control.
Comparison between the groups (while taking into consideration variables like diet and smoking habits) could prove whether Metformin can slow the progress of diseases, prevent them, and even increase life expectancy.